Synthetic self-amplifying MRNA molecules with secretion antigen and immunomodulator
AssigneeSunVax mRNA Therapeutics Inc.
InventorsYingzhong Li, Libin Zhang
Life of this patent
Estimating the term…
Abstract
Lipid nanoparticle (LNP) encapsulating self-amplifying mRNA, compositions, and methods of using the novel nucleic acid constructs and compositions are disclosed. LNP constructs include novel ionizable lipid. Novel sa-mRNA constructs encode a modified SARS-COV-2 spike protein, wherein the polynucleotide has been truncated to not include nucleotides encoding a SARS-COV-2 transmembrane domain and short cytosolic domain amino acids and immunomodulators. Sa-mRNAs are useful in for use as a therapeutic, diagnostic and/or prophylactic agent to mammalian cells or organs.
Claims27
A self-amplifying mRNA comprising from 5′ to 3′:
- a) a 5′ untranslated region (UTR), nucleotides 1869 to 9441 of SEQ ID NO:
- 35 with one or more substitutions selected from C4491A/T5177C/A5361C/A5735G/A6452G/G7663A/A7765G, one or more genes of interest (GOI) that optionally comprises a linker (L) at the 5′ and/or 3′ end, a 3′ UTR, and a poly-adenosine (poly-A) tail;
- or
- b) a 5′ UTR, nucleotides 1869 to 9441 of SEQ ID NO:
- 36, the GOI that optionally comprises the L at the 5′ and/or 3′ end, a 3′ UTR, and a poly-A tail;
- or
- c) a 5′ UTR, nucleotides 1869 to 9441 of SEQ ID NO:
- 36 with one or more substitutions selected from C4491A/T5177C/A5361C/A5735G/A6452G/G7663A/A7765G, the GOI that optionally comprises the L at the 5′ and/or 3′ end, a 3′ UTR, and a poly-A tail.
Dependencies are inferred from the claim text.